DeLLphi-315 (20250046)

A Phase 3, Open-label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in participants with relapsed extensive-stage Small Cell Lung Cancer after Platinum-based First-line chemotherapy.

This is the trial summary as assessed on clinicaltrials.gov. You can check this on this direct link:

https://clinicaltrials.gov/study/NCT07778316

Trial Design:



IV = intravenous; N = total number of participants; n = number of participants; Q2W = every 2 weeks; SC = Subcutaneous; W = week

Inclusion criteria:

1. Histologically or cytologically confirmed small-cell lung carcinoma with demonstrated radiographic progression or relapse after only 1 platinum-based regimen
2. History of CNS metastases are allowed with considerations defined in the protocol
3. Minimum life expectancy of 12 weeks
4. Adequate organ function (eg, eGFR >30mL/min)
5. ECOG of 0 or 1
6. Available archival tumour tissue from diagnosis

Exclusion criteria:

1. Previous diagnosis of NSCLC with EGFR activating mutation that has transformed to SCLC, or mixed SCLC and NSCLC histology
2. More than 1 prior line of anticancer therapy for SCLC
3. Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the DLL3 pathway
4. Prior systemic anticancer therapy within 30 days of enrolment
5. Receiving another anticancer therapy for a malignancy other than SCLC
6. Uncontrolled active systemic infection within 7 days prior to the first dose of study treatment